行情

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

1.180
-0.070
-5.60%
盘后: 1.180 0 0.00% 18:37 01/21 EST
开盘
1.220
昨收
1.250
最高
1.240
最低
1.150
成交量
278.64万
成交额
--
52周最高
6.60
52周最低
1.150
市值
1.21亿
市盈率(TTM)
-1.9562
分时
5日
1月
3月
1年
5年
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.94% at $0.25
Benzinga · 3天前
Psychedelic Stock Gainers And Losers From January 18, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 1.90% at $1.07
Benzinga · 4天前
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?
Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for investors and entrepreneurs alike.
Benzinga · 2021/12/30 14:37
BRIEF-Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
reuters.com · 2021/12/21 21:17
Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted a stock option to purchase 75,000 share...
PR Newswire · 2021/12/21 21:05
Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 11th Annual LifeSci Partner...
PR Newswire · 2021/12/16 13:00
BRIEF-Seelos Therapeutics Files For Resale Of Up To 3.2 Million Shares
reuters.com · 2021/12/13 21:27
Seelos Therapeutics secures composition of matter patent in Japan for SLS-007
Seelos Therapeutics (SEEL -3.7%) has received an issued patent from the Japanese Patent Office (Number 6968839, titled: Structure-Based Peptide Inhibitors Of Alpha-Synuclein Aggregation), covering the composition of matter for SLS-007,
Seekingalpha · 2021/12/06 14:41
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解SEEL最新的财务预测,通过SEEL每股收益,每股净资产,每股现金流等数据分析Seelos Therapeutics Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

33.33%强力推荐
66.67%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测SEEL价格均价为9.50,最高价位14.00,最低价为6.00。
最高14.00
均价9.50
最低6.00
现价1.180
EPS
实际EPS
预期EPS
-0.22-0.17-0.11-0.06
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 126
机构持股: 4,044.32万
持股比例: 39.50%
总股本: 1.02亿
类型机构数股数
增持
39
539.47万
建仓
23
120.04万
减持
25
499.75万
平仓
18
226.69万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.92%
制药与医学研究
-1.11%
高管信息
Chairman/President/Chief Executive Officer/Director
Raj Mehra
Chief Financial Officer
Michael Golembiewski
Other
Anthony Marciano
Director
Margaret Dalesandro
Director
Richard Pascoe
Independent Director
Brian Lian
Independent Director
Daniel O'Connor
暂无数据
SEEL 简况
Seelos Therapeutics, Inc.(原名:Apricus Biosciences, Inc.),是一家临床阶段的生物制药公司。该公司致力于开发治疗中枢神经系统、呼吸系统疾病的技术和治疗方法。公司正在开发其领先计划SLS-002和SLS-006。该公司还致力于开发多种临床前程序,包括SLS-008,SLS-010和SLS-012。SLS-002是鼻内外消旋氯胺酮,具有两种研究性新药应用(INDs),用于治疗创伤后应激障碍(PTSD)和自杀性抑郁症中。作为早期帕金森病患者的单药治疗和减少左旋多巴剂量(L-DOPA)的辅助治疗,SLS-006致力于推动其候选产品进入最后阶段试验。SLS-007是一种基于肽的方法,针对非淀粉样蛋白成分核心(NACore)。

微牛提供Seelos Therapeutics Inc(NASDAQ-SEEL)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的SEEL股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SEEL股票基本功能。